Roche's HDL play

Roche's deal for JTT-705 puts the company into the increasingly hot HDL cholesterol space with a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors increase HDL levels and are expected to be used to treat dyslipidemia, especially in metabolic syndromes. Pfizer Inc.

Read the full 429 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE